Results 171 to 180 of about 22,921 (208)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2005
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status.
Jean-Pierre J, Issa +2 more
+7 more sources
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status.
Jean-Pierre J, Issa +2 more
+7 more sources